866-997-4948(US-Canada Toll Free)

Chronic Kidney Disease - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 195 Pages

Chronic Kidney Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) - Overview 8
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 29
Angion Biomedica Corp 29
apceth Biopharma GmbH 29
Astellas Pharma Inc 30
AstraZeneca Plc 30
Bayer AG 31
BLR Bio LLC 31
Boehringer Ingelheim GmbH 32
Boryung Pharmaceutical Co Ltd 32
Cellmid Ltd 33
Chugai Pharmaceutical Co Ltd 33
Complexa Inc 34
Corvidia Corp 34
CTI BioPharma Corp 35
Evotec AG 35
F. Hoffmann-La Roche Ltd 36
Gilead Sciences Inc 36
GNI Group Ltd 37
Lupin Ltd 37
Navya Biologicals Pvt Ltd 38
Nippon Zoki Pharmaceutical Co Ltd 38
Novartis AG 39
Otsuka Holdings Co Ltd 39
Prismic Pharmaceuticals Inc 40
Prolong Pharmaceuticals LLC 40
ProMetic Life Sciences Inc 41
Reata Pharmaceuticals Inc 41
Regulus Therapeutics Inc 42
Relypsa Inc 42
Resverlogix Corp 43
Spotlight Innovation Inc 43
Taisho Pharmaceutical Co Ltd 44
Toray Industries Inc 44
Tricida Inc 45
Unity Biotechnology Inc 45
Vascular BioSciences 46
VESSL Therapeutics Ltd 46
Vicore Pharma AB 47
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles 48
(palmidrol + silibinin) - Drug Profile 48
ambrisentan - Drug Profile 49
ANG-3070 - Drug Profile 52
ANG-3281 - Drug Profile 53
ANG-3586 - Drug Profile 54
Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile 55
apabetalone - Drug Profile 56
AS-2444697 - Drug Profile 68
bardoxolone methyl - Drug Profile 69
BI-655088 - Drug Profile 75
BKE-001 - Drug Profile 76
BLR-400 - Drug Profile 77
C-21 - Drug Profile 78
CAB-101 - Drug Profile 81
calcium succinate - Drug Profile 83
CAR Peptide - Drug Profile 84
cardiotoxin - Drug Profile 85
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 86
COR-001 - Drug Profile 87
CXA-10 - Drug Profile 88
dapagliflozin propanediol - Drug Profile 89
Drug for Kidney Diseases - Drug Profile 96
Drug to Activate sGC for Chronic Kidney Disease - Drug Profile 97
EOS-789 - Drug Profile 98
F-351 - Drug Profile 99
finerenone - Drug Profile 101
FM-1302 - Drug Profile 103
KBP-5074 - Drug Profile 104
LHW-090 - Drug Profile 106
MultiGeneGraft - Drug Profile 107
NAV-003 - Drug Profile 108
NZ-419 - Drug Profile 109
obinutuzumab - Drug Profile 110
pacritinib - Drug Profile 118
patiromer sorbitex calcium - Drug Profile 131
PBI-4050 - Drug Profile 135
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 142
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 143
Sanguinate - Drug Profile 145
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 148
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease - Drug Profile 149
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 150
Small Molecules for Chronic Kidney Disease - Drug Profile 151
Small Molecules for Chronic Kidney Disease - Drug Profile 152
SP-20103 - Drug Profile 153
SPR-494 - Drug Profile 154
Stem Cell Therapy for Chronic Kidney Disease - Drug Profile 155
Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile 156
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 157
tesidolumab - Drug Profile 158
tolvaptan - Drug Profile 160
torsemide ER - Drug Profile 164
TRC-101 - Drug Profile 165
TS-143 - Drug Profile 166
verinurad - Drug Profile 167
Vida-5 - Drug Profile 169
VS-105 - Drug Profile 170
Wnt-001 - Drug Profile 171
YS-1402 - Drug Profile 172
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 173
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 175
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 176
Featured News & Press Releases 176
Appendix 190
Methodology 190
Coverage 190
Secondary Research 190
Primary Research 190
Expert Panel Validation 190
Contact Us 190
Disclaimer 191

List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *